Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.48 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.48 |
| ▸ | CTSK | P43235 | 6/20 | 0.47 |
| ▸ | UTS2R | Q9UKP6 | 4/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4768735 | 0.90 | CTSK (0.36) | TAS1R3TAS1R1CTSKUTS2RNPC1 | |
| SCHEMBL4765349 | 0.84 | CTSK (0.46) | TAS1R3TAS1R1CTSKUTS2RCTSB | |
| SCHEMBL4765345 | 0.84 | CTSK (0.46) | TAS1R3TAS1R1CTSKUTS2RCTSB | |
| SCHEMBL4766646 | 0.83 | CTSK (0.45) | CTSKUTS2RCTSBCTSSNPC1 | |
| SCHEMBL6771256 | 0.82 | CTSK (0.50) | TAS1R3TAS1R1CTSKUTS2RCTSB | |
| SCHEMBL4765540 | 0.82 | NPC1 (0.37) | TAS1R3TAS1R1CTSKCTSBCTSS | |
| SCHEMBL4761946 | 0.81 | TAS1R3 (0.50) | TAS1R3TAS1R1CTSKCTSBCTSS | |
| SCHEMBL6765735 | 0.81 | CTSK (0.46) | TAS1R3TAS1R1CTSKUTS2RCTSB | |
| SCHEMBL4838791 | 0.81 | CTSK (0.46) | TAS1R3TAS1R1CTSKUTS2RCTSB | |
| SCHEMBL7037396 | 0.81 | NPC1 (0.39) | NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1320370-A4 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORP (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1320370-A1 | METHOD OF TREATMENT | SmithKline Beecham Corporation (US) | 2003-06-25 | — | — | EP | disclosed |
| WO-2002017924-A1 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORPORATION (GB) | 2002-03-07 | — | — | WO | disclosed |